

europaean journal of gynaecological oncology

an International Journal

Editors-in-Chief

A. Onnis **P. Bószé**
Montréal (Canada) Budapest (Hungary)

Associate Editor

M. Marchetti
Montréal (Canada)

Assistant Editor

J. Wilson
San Diego - CA (USA)

Editorial Board

Allen H.H., <i>London, Ontario (Canada)</i>	Friedrich M., <i>Luebeck (Germany)</i>	Marth C., <i>Innsbruck (Austria)</i>
Anteby S.O., <i>Jerusalem (Israel)</i>	Fuller A.F. Jr., <i>Boston, MA (USA)</i>	Massuger Leon F.A.G., <i>Nijmegen (The Netherlands)</i>
Audet-Lapointe P., <i>Montreal (Canada)</i>	Geisler H.E., <i>Indianapolis, IN (USA)</i>	Menczer J., <i>Savyon (Israel)</i>
Ayhan A., <i>Ankara (Turkey)</i>	Gerbaulet A., <i>Villejuif (France)</i>	Monsonogo J., <i>Paris (France)</i>
Balat O., <i>Graziantep (Turkey)</i>	Gorins A., <i>Paris (France)</i>	Pinotti A., <i>São Paulo (Brazil)</i>
Barber H.K., <i>New York, NY (USA)</i>	Heintz A.P.M., <i>Utrecht (The Netherlands)</i>	Piver S.M., <i>Buffalo, NY (USA)</i>
Basta A., <i>Krakow (Poland)</i>	Ioannidou-Mouzaka L., <i>Athens (Greece)</i>	Rakar S., <i>Ljubljana (Slovenia)</i>
Bender H.C., <i>Dusseldorf (Germany)</i>	Jordan J.A., <i>Birmingham, England (UK)</i>	Raju K.S., <i>London, England (UK)</i>
Benedetti Panici P.L., <i>Rome (Italy)</i>	Karseladze A.I., <i>Moscow (Russia)</i>	Shepherd J.H., <i>London, England (UK)</i>
Charkviani T., <i>Tbilisi (Georgia)</i>	Klastersky J., <i>Bruxelles (Belgium)</i>	Stelmachów J., <i>Warsaw (Poland)</i>
Dargent D., <i>Lyon (France)</i>	Kubista E., <i>Vienna (Austria)</i>	Ungár L., <i>Budapest (Hungary)</i>
De Oliveira C.F., <i>Coimbra (Portugal)</i>	Kudelka A.P., <i>Houston, TX (USA)</i>	Vermorken J.B., <i>Edegem (Belgium)</i>
Dexeus S. Jr., <i>Barcelona (Spain)</i>	Maggino T., <i>Padua (Italy)</i>	Vírtej P., <i>Bucharest (Romania)</i>
De Palo G., <i>Milan (Italy)</i>	Markowska J., <i>Poznan (Poland)</i>	Wang P.-H., <i>Taipei (Taiwan)</i>
Di Paola G.R., <i>Buenos Aires (Argentina)</i>		Winter R., <i>Graz (Austria)</i>
Di Re F., <i>Milan (Italy)</i>		Yokoyama Y., <i>Hiroasaki (Japan)</i>
Di Saia P., <i>Orange, CA (USA)</i>		

Publishing Organization (M. Morsani):

I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroun-online.com - www.irog.net

Editorial Office (M. Critelli):

Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by **CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.**

European Journal of Gynaecological Oncology

www.irog.net

General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distinguished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the diffusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted six months before publication and will be published free of charge.

BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.

COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.

ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2H3, Tél. 514.4893242-4893640, Fax 514.4854513, E-mail: canlux@mggroup-online.com - www.irog.net

RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate information, the publisher accepts no responsibility for the consequences of faulty or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.

SUBSCRIPTION INFORMATION

The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is \$390 US for Institutions, \$200 US for Individuals. For airmail add \$30, for receipt add \$10 US. Single copy prepaid cost \$95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner's - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. **Only US Funds are accepted.** No bank transfers.

Claims for missing issues can be honoured up to six months. **Changes of address:** allow six weeks for all changes to become effective. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and **any communication and requests should be addressed to** I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT.

European Journal of Gynaecological Oncology

www.irog.net

Instructions to Authors

SUBMISSION OF MANUSCRIPTS

Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Storione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the "Distinguished Expert Series" should be submitted to P. Bószé, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1) 275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers' suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publication cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author's experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and application thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS

The Journal follows the "Uniform requirements for manuscripts submitted to biomedical journals" published in the *New England Journal of Medicine* 1991, 324, 424-8 and in the *British Medical Journal* 1991, 302.

Three *manuscripts*, typed and double spaced should be submitted **with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0**. Manuscripts without an electronic disk will not be accepted. **A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been published or submitted for publication elsewhere.** Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the *Corresponding Author*, responsible for revision and approval of the proofs, should be indicated. **Full-length articles should not exceed 8 printed pages including tables and references.**

After the *title page* (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: *Summary* (purpose of investigation, methods, results, conclusion - about 150 words), *Key words*, *Content* (a 20-word summary), *Introduction*, *Materials and Methods*, *Results*, *Discussion*, *Conclusion*, *Acknowledgement* (if any), *References*, *Tables*, *Legends*.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author's name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. **If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).**

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first citation in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in *Index Medicus*. The titles of journals should be abbreviated according to the style used in *Index Medicus*.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors' surname and initials (if more than six names, give six followed by "et al."), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors' surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline **the proofs will be considered approved**. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS

The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. **Only payments in US dollars will be accepted.** No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.

In memoriam	353
DISTINGUISHED EXPERT SERIES	
Serous borderline ovarian tumors: Where are we now?	355
A.I. Karseladze - <i>Moscow, RUSSIA</i> Revision of the up-to-date problems of serous borderline ovarian tumor pathology, the microscopic diagnosis and prognostic criteria.	
REVIEW ARTICLES	
Immunohistochemical tumour markers in endometrial carcinoma	363
E. Ioachin - <i>Ioannina, GREECE</i> The interrelationships of biomarkers show that these genetic dysregulations can be implicated in the control of cell proliferation and through these pathways might contribute to the multistep process of endometrial carcinogenesis.	
Screening for cervical cancer – an evidence-based approach	372
A. Fraser, S. Hellmann, L. Leibovici, H. Levavi - <i>Tel Aviv, ISRAEL</i> Using an evidence-based approach we examined the evidence for the effectiveness of cervical cancer screening by Pap smears, applied findings to Israeli data and assessed the implications for current screening policy.	
ORIGINAL ARTICLES	
Down regulation of estrogen receptor expression is an early event in human papillomavirus infected cervical dysplasia	376
R.L.M. Bekkers, I.A.M. van der Avoort, W.J.G. Melchers, J. Bulten, P.C.M. de Wilde, L.F.A.G. Massuger - <i>Nijmegen, THE NETHERLANDS</i> The role of high-risk HPV, estrogen receptor, progesterone receptor and MIB-1 expression in cervical dysplasia and adjacent normal cervical epithelium is presented.	
Estradiol metabolites are potent mitogenic substances for human ovarian cancer cells	383
H. Seeger, D. Wallwiener, E. Kraemer, A.O. Mueck - <i>Tuebingen, GERMANY</i> Certain estradiol metabolites stimulate the proliferation of human ovarian cancer cells.	
Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma	386
B. Piura, M. Meirovitz - <i>Beer-Sheva, ISRAEL</i> Weekly carboplatin demonstrated considerable activity and low and well tolerated toxicity in ten heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.	
Preoperative diagnosis of malignant transformation in mature cystic teratoma of the ovary	391
Y. Yamanaka, Y. Tateiwa, H. Miyamoto, Y. Umemoto, Y. Takeuchi, K. Katayama, K. Hashimoto - <i>Kobe, JAPAN</i> SCC value and tumor size may be useful in the preoperative diagnosis of malignant transformation arising from mature cystic teratomas of the ovary.	
Can viral load, semi-quantitatively evaluated, of human papillomavirus predict cytological or histological outcome in women with atypical squamous or glandular cells of undetermined significance cytology?	393
C.W.M. Wensveen, M.J. Kagie, N.J.D. Nagelkerke, R.W. Veldhuizen, J.B.M.Z. Trimbos - <i>Rotterdam, THE NETHERLANDS</i> Viral load, semi-quantitatively evaluated, cannot predict the risk of CIN or cytological regression in women with ASCUS/AGUS cytology.	
Relationship between chemotherapy with paclitaxel, cisplatin, vinorelbine and titanocene dichloride and expression of proliferation markers and tumour suppressor gene p53 in human ovarian cancer xenografts in nude mice	398
H.-C. Kolberg, C. Villena-Heinsen, M.-M. Deml, S. Kraemer, K. Diedrich, M. Friedrich - <i>Lübeck, GERMANY</i> In this investigation no relationship between chemotherapy and the markers of proliferation or p53 could be seen in a nude mice model.	

- Loss of basement membrane heparan sulfate expression is associated with tumor progression in endometrial cancer** 403
 Hasengaowa, J. Kodama, T. Kusumoto, Y. Shinyo, N. Seki, K. Nakamura, A. Hongo, Y. Hiramatsu - *Okayama, JAPAN*
 The loss of basement membrane heparan sulfate glycosaminoglycan expression is closely associated with tumor progression in endometrial cancer.
- The activity of cancer procoagulant in cases of uterine leiomyomas** 407
 M. Jozwik, S.D. Szajda, Z. Skrzydlewski, M. Jozwik, S. Sulkowski - *Bialystok, POLAND*
 Uterine leiomyomas, representing benign genital neoplasia, synthesize cancer procoagulant-like malignant tumors, but to a lesser degree.
- Effects of mitomycin C on radiation-induced cell death in human cervical squamous cell carcinomas** 411
 T. Tanaka, N. Umesaki - *Wakayama, JAPAN*
 Combination of mitomycin C with radiotherapy for patients with cervical squamous cell carcinoma was evaluated by *in vitro* experiments.
- Uterine adenocarcinoma diagnosed following hysteroscopic resection of an intrauterine tumour** 415
 E. González Bosquet, M. Sunol, J. Callejo, J.M. Lailla - *Barcelona, SPAIN*
 Uterine adenocarcinoma is a rare tumour. A case diagnosed following hysteroscopic resection of an endometrial tumour is presented.
- The role of pelvic exenteration for treatment of pelvic malignancy - a nine-year experience** 418
 D. Wydra, J. Emerich, K. Ciach, S. Sawicki, A. Marciniak - *Gdańsk, POLAND*
 Twenty-three patients who underwent pelvic exenteration for local advanced gynecological and rectal malignancies were analyzed for complications and survival time.
- Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy - preliminary results** 423
 M. Bidziński, A. Danska-Bidzińska, I. Ziółkowska-Seta, P. Derlatka, P. Sobiczewski, P. Raczyński - *Warsaw, POLAND*
 To assess the value of neoadjuvant chemotherapy administered after 3 and 6 cycles of taxanes and platinum 50 ovarian cancer patients were analyzed. These results were compared with the results of 269 patients treated traditionally by using primary surgery.
- Role of human papillomavirus testing in reducing the number of surgical treatments for precancerous cervical lesions** 427
 E. Vrtačnik-Bokal, S. Rakar, N. Jančar, A. Možina, M. Poljak - *Ljubljana, SLOVENIA*
 Complementary HPV testing in detection of precancerous cervical lesions reduces the number of unnecessary surgical treatment procedures.
- Radiation enhances cisplatin-sensitivity in human cervical squamous cancer cells *in vitro*** 431
 T. Tanaka, K. Yukawa, N. Umesaki - *Wakayama, JAPAN*
 Radiation enhances cisplatin-sensitivity but cisplatin does not affect radiosensitivity in human cervical squamous cell carcinoma cells *in vitro*.
- Hysteroscopic findings of endometrial carcinoma. Evaluation of 104 cases** 434
 O. Triolo, F. Antico, V. Palmara, V. Benedetto, S. Panama, P.A. Nicotina - *Messina, ITALY*
 Some hysteroscopic findings highly suggestive of endometrial carcinoma were confirmed histologically after guided biopsy during diagnostic hysteroscopy.
- Ultrasound and surgery for gall bladder carcinoma during pregnancy** 437
 M. Gojnic, V. Dugalic, S. Vidaković, M. Papic, S. Milićević, M. Pervulov - *Belgrade, SERBIA AND MONTENEGRO*
 Gall bladder carcinoma is the most common carcinoma of the biliary tract and the fifth most common malignant tumor of the gastrointestinal tract. The patients usually have no symptoms at all or non-specific symptoms are present. The therapy for gall bladder carcinoma is complete removal. Unfortunately, in 80% of the cases the survival period is less than one year.
- Late relapse of epithelial ovarian cancer: A single institution experience** 439
 A. Bamias, E. Efstathiou, M. Vassilakopoulou, V. Koutsoukou, C. Papadimitriou, A. Rodolakis, D. Mitsibounas, G. Vlahos, M.A. Dimopoulos - *Athens, GREECE*
 A single institution's experience is described of a rare phenomenon of ovarian cancer: late relapses after surgery and first-line chemotherapy.

CASE REPORTS

- Primary pure squamous cell carcinoma of the breast: A case report and review of the literature** 443
 J.A. Makarem, J. Abbas, Z.K. Otrrock, A.N. Tawil, A.T. Taher, A.I. Shamseddine - *Beirut, LEBANON*
 A case of primary squamous cell carcinoma of the breast with a review of the literature for all similar cases is reported.
- Teratomas of the ovary: a clinico-pathological evaluation of 87 patients from one institution during a 10-year period** 446
 K. Papadias, E. Kairi-Vassilatou, K. Kontogianni-Katsaros, J. Argeitis, A. Kondis-Pafitis, G. Greatsas - *Athens, GREECE*
 Retrospectively the clinical and pathological characteristics of a large series of 87 teratomas of the ovary were analyzed. Teratomas are common tumors at any age, with a low rate of complications and malignant transformation.
- Adenosquamous carcinoma of the uterine cervix - adjuvant chemotherapeutic treatment with paclitaxel and carboplatin; a case report** 449
 V. Radić, V. Kukura, S. Ciglar - *Zagreb, CROATIA*
 A case of Stage IV cervical carcinoma treated with paclitaxel and carboplatin after cytoreductive surgery and liver metastases treated by sclerotherapy is reported.
- False-positive fluorine-18 fluorodeoxy-D-glucose positron emission tomography imaging caused by retained gauze in a woman with recurrent ovarian cancer: A case report** 451
 M-Y. Chen, K-K. Ng, S-Y. Ma, T-I. Wu, T-C. Chang, C-H. Lai - *Taoyuan, TAIWAN*
 False-positive FDG-PET imaging caused by retained gauze in a case of recurrent ovarian cancer is presented to highlight the limitation of the PET scan.
- A large benign vascular neoplasm of the male breast. A case report and review of the literature** 454
 A. Kondi-Pafitis, E. Kairi-Vassilatou, D. Grapsa, I. Kalkounou, G. Vassilikostas, I. Psychogios - *Athens, GREECE*
 A case of a 77-year-old man with a breast hemangioma is presented. The rarity of the lesion and its differential diagnosis from angiosarcoma and other vascular tumors are discussed.
- Non-Hodgkin's lymphoma complicating pregnancy: A case report** 457
 S. Guven, O.I. Ozcebe, Z.S. Tuncer - *Ankara, TURKEY*
 Non-Hodgkin's lymphoma complicating late pregnancy may be managed successfully with expectant management for fetal lung maturation.
- Ectopic decidua mimicking metastatic lesions - Report of three cases and review of the literature** 459
 A. Kondi-Pafitis, D. Grapsa, K. Kontogianni-Katsarou, K. Papadias, E. Kairi-Vassilatou - *Athens, GREECE*
 Histopathological characteristics and differential diagnosis of ectopic decidua mimicking metastatic lesions are presented.
- Large intramyometrial cystic adenomyosis: a hysteroscopic approach with bipolar resectoscope: Case report** 462
 M. Giana, F. Montella, D. Surico, A. Vigone, C. Bozzola, G. Ruspa - *Novara, ITALY*
 Transvaginal ultrasound together with hysteroscopy is highly specific to diagnose and treat this kind of adenomyotic lesion.
- Cutaneous metastasis of endometrial carcinoma with hemorrhagic nodules and papules** 464
 M. Baydar, M. Dikilitas, A. Sevinc, S. Senel, F. Senel, I. Aydogdu - *Malatya, TURKEY*
 A patient with endometrial carcinoma presenting with multiple metastatic, nodular, hemorrhagic cutaneous lesions located at the initial surgery and radiotherapy site is reported.
- Letter to the Editor 466

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY

Vol. XXVI, Number 4, 2005

ISSN: 0392-2936

I.R.O.G. CANADA, Inc.

Publisher office: 4900 Côte St. Luc - Apt. 212 - Montréal, Québec H3W 2H3 (Canada) - Tél.: (514) 4893640-4893242 - Fax: (514) 4854513

E-mail: canlux@mgroup-online.com - www.irog.net

ALL RIGHTS RESERVED

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopies, recordings, nor any information storage and retrieval system without written permission from the copyright owner.

Printed in Italy